Top

memo - Magazine of European Medical Oncology

Published in:

01-04-2015 | short review

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia

Authors: Lukas Weiss, MD, PhD, Thomas Melchardt, MD, Alexander Egle, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2015

Abstract

B-cell receptor (BCR) inhibitors represent an exciting new treatment modality in chronic lymphocytic leukemia (CLL). Currently, ibrutinib monotherapy as well as idelalisib in combination with rituximab are approved by the European Medical Agency for the treatment of all patients with relapsed/refractory CLL and for first-line treatment of patients with deletion 17p or TP53 mutation unsuitable for chemoimmunotherapy. The results of ongoing trials with these and other BCR inhibitors are expected to lay the basis for approval in further indications, but have to be awaited. Above all, BCR inhibitors have shown to be able to fill the gap of urgently needed therapies for the elderly and comorbid CLL patient as well as the CLL patient with deletion 17p. BCR inhibitors might also challenge the role of allogeneic stem cell transplantation in CLL in the future.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80. (doi:10.1073/pnas.1004594107. Epub 2010 Jul 6. PubMed PMID: 20615965; PubMed Central PMCID: PMC2919935).CrossRefPubMedCentralPubMed

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591–4. (doi:10.1182/blood-2010-03-275305. Epub 2010 Oct 19. PubMed PMID: 20959606; PubMed Central PMCID: PMC3694505).CrossRefPubMedCentralPubMed

OʹBrien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58. (doi:10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10. PubMed PMID: 24332241; PubMed Central PMCID: PMC4134524).CrossRefPubMedCentralPubMed

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94. (doi:10.1200/JCO.2012.42.7906. Epub 2012 Oct 8. PubMed PMID: 23045577).CrossRefPubMed

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, OʹBrien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. (doi:10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786. PubMed PMID: 23782158; PubMed Central PMCID: PMC3772525).CrossRefPubMedCentralPubMed

Byrd JC, Brown JR, OʹBrien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. (doi:10.1056/NEJMoa1400376. Epub 2014 May 31. PubMed PMID: 24881631; PubMed Central PMCID: PMC4134521).CrossRefPubMedCentralPubMed

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Resistance mechanisms for the Brutonʹs tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94. (doi:10.1056/NEJMoa1400029. Epub 2014 May 28. PubMed PMID: 24869598; PubMed Central PMCID: PMC4144824).CrossRefPubMedCentralPubMed

Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Jeyakumar G, Ferrajoli A, Faderl SH, Cardenas-Turanzas M, Lerner S, Zacharian G, Huang X, Kantarjian H, OʹBrien S. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase ii trial in 40 patients. Blood. 2013;122. (ASH Meeting 2013; abstra 675)

Brown JR, Barrientos JC, Barr PM, Flinn I, Burger JA, Salman Z, Clow F, James DF, Graef T, Friedberg J, Rai KR, OʹBrien S. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. Blood. 2013;122. (ASH Meeting 2013; abstr 525)

10.

Brown JR, Furman RR, Flinn I, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, Johnson DM, Li D, Dansey RD, Jahn TM, Byrd JC. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory CLL. ASCO Meeting Abstracts, June 17, 2013:7003.

11.

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, OʹBrien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. (doi:10.1056/NEJMoa1315226. Epub 2014 Jan 22. PubMed PMID: 24450857).CrossRefPubMedCentralPubMed

12.

Hallek M. Blood 2012 June 4 (e-letter). http://bloodjournal.hematologylibrary.org/content/111/12/5446/reply.

13.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. (doi:10.1182/blood-2007-06-093906. Epub 2008 Jan 23. Erratum in: Blood. 2008 Dec 15;112(13):5259. PubMed PMID: 18216293; PubMed Central PMCID: PMC2972576).

14.

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, OʹBrien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7. (doi:10.1182/blood-2013-09-527853. Epub 2014 Jan 10. PubMed PMID: 24415539; PubMed Central PMCID: PMC3962160).CrossRefPubMedCentralPubMed

15.

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E. Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014 Oct 9. pii: blood-2014–07-586826. [Epub ahead of print] PubMed PMID: 25301705.

Title: Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
Authors: Lukas Weiss, MD, PhD
Thomas Melchardt, MD
Alexander Egle, MD
Publication date: 01-04-2015
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 1/2015
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0186-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

PET in lymphoma: who, when, how often, pitfalls?

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load

Optimal follow-up of ovarian cancer patients

Radiotherapy for brain metastases: are we getting better?

Lymphoma: anything new?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer